ESR1 and breast carcinoma: Figure 1 illustrates the heterogeneity of the HR+ breast cancer TME, highlighting molecular heterogeneity (HLA-I downregulation, PD-L1 and ER expression), cellular diversity (varied immune populations, TAM polarization, and rare TLS) and spatial diversity (immune cell distribution).